|
|
Prepublished online as a Blood First Edition Paper on February 27, 2003; DOI 10.1182/blood-2002-06-1864.
Previous Article | Table of Contents | Next Article 
Blood, 15 June 2003, Vol. 101, No. 12, pp. 4975-4981
NEOPLASIA
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
Jenny Orchard,
Richard Garand,
Zadie Davis,
Gavin Babbage,
Surinder Sahota,
Estella Matutes,
Daniel Catovsky,
Peter W. Thomas,
Hervé Avet-Loiseau, and
David Oscier
From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom.
We analyzed lymphocyte morphology, histology, immunophenotype, immunoglobulin heavy chain (IgVH) gene mutations, and clinical course in 80 unselected patients presenting with circulating t(11;14) lymphocytes. Of the 80 patients, 43 had peripheral lymphadenopathy (nodal group), and histology confirmed mantle cell lymphoma (MCL) in all. There were 37 patients with no lymphadenopathy (nonnodal group); 13 of 37 had histology, all showing MCL. IgVH genes were unmutated in 28 (90%) of 31 nodal and 15 (44%) of 34 nonnodal cases (P = .0001); CD38 was positive in 32 (94%) of 34 nodal and 16 (48%) of 33 nonnodal cases (P < .001); 41 (95%) of 43 nodal patients required immediate treatment compared with 18 (49%) of 37 nonnodal patients who had indolent disease (P < .0001). Median survival (95% confidence interval) was 30 months (10-50) in the nodal group and 79 months (22-136) in the nonnodal group (P = .005). Mutation status did not statistically affect survival, but of 6 long-term survivors (> 90 months) all were nonnodal and 5 of 5 had mutated IgVH genes. Lymphocyte morphology was heterogeneous in both groups: typical MCL in 56 cases (34 nodal, 22 nonnodal), blastoid MCL in 8 cases (3 nodal, 5 nonnodal), and small-cell MCL in 16 cases (6 nodal, 10 nonnodal, P = .12). Matutes immunophenotyping score was 1 in 65 cases and 2 in 15 (8 nodal, 7 nonnodal). We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgVH genes may help identify patients with indolent disease.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Forconi, E. Sozzi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, L. Rigacci, F. Gherlinzoni, R. Cantaffa, A. Baraldi, et al.
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
Blood,
November 19, 2009;
114(21):
4696 - 4702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gao, L. Peterson, B. Nelson, C. Goolsby, and Y.-H. Chen
Immunophenotypic Variations in Mantle Cell Lymphoma
Am J Clin Pathol,
November 1, 2009;
132(5):
699 - 706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Navarro, S. Bea, V. Fernandez, M. Prieto, I. Salaverria, P. Jares, E. Hartmann, A. Mozos, A. Lopez-Guillermo, N. Villamor, et al.
MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas
Cancer Res.,
September 1, 2009;
69(17):
7071 - 7078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ghielmini and E. Zucca
How I treat mantle cell lymphoma
Blood,
August 20, 2009;
114(8):
1469 - 1476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sander, L. Bullinger, E. Leupolt, A. Benner, D. Kienle, T. Katzenberger, J. Kalla, G. Ott, H. K. Muller-Hermelink, T. F.E. Barth, et al.
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations
Haematologica,
May 1, 2008;
93(5):
680 - 687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol.,
October 1, 2007;
60(10):
1076 - 1085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al.
Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors
J. Clin. Oncol.,
July 1, 2007;
25(19):
2770 - 2777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mestre-Escorihuela, F. Rubio-Moscardo, J. A. Richter, R. Siebert, J. Climent, V. Fresquet, E. Beltran, X. Agirre, I. Marugan, M. Marin, et al.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Blood,
January 1, 2007;
109(1):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Rubio-Moscardo, J. Climent, R. Siebert, M. A. Piris, J. I. Martin-Subero, I. Nielander, J. Garcia-Conde, M. J. S. Dyer, M. J. Terol, D. Pinkel, et al.
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
Blood,
June 1, 2005;
105(11):
4445 - 4454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Liu, J. Wang, and E. M. Epner
Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences
Blood,
October 15, 2004;
104(8):
2505 - 2513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Babbage, R. Garand, N. Robillard, N. Zojer, F. K. Stevenson, and S. S. Sahota
Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events
Blood,
April 1, 2004;
103(7):
2795 - 2798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kienle, A. Krober, T. Katzenberger, G. Ott, E. Leupolt, T. F. E. Barth, P. Moller, A. Benner, A. Habermann, H. K. Muller-Hermelink, et al.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome
Blood,
October 15, 2003;
102(8):
3003 - 3009.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|